Cargando…
Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries
Oxytocin is recommended by the World Health Organisation as the most effective uterotonic for the prevention and treatment of postpartum haemorrhage. The requirement for parenteral administration by trained healthcare providers and the need for the drug solution to be maintained under cold-chain sto...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871608/ https://www.ncbi.nlm.nih.gov/pubmed/24376618 http://dx.doi.org/10.1371/journal.pone.0082965 |
_version_ | 1782296846250541056 |
---|---|
author | Prankerd, Richard J. Nguyen, Tri-Hung Ibrahim, Jibriil P. Bischof, Robert J. Nassta, Gemma C. Olerile, Livesey D. Russell, Adrian S. Meiser, Felix Parkington, Helena C. Coleman, Harold A. Morton, David A. V. McIntosh, Michelle P. |
author_facet | Prankerd, Richard J. Nguyen, Tri-Hung Ibrahim, Jibriil P. Bischof, Robert J. Nassta, Gemma C. Olerile, Livesey D. Russell, Adrian S. Meiser, Felix Parkington, Helena C. Coleman, Harold A. Morton, David A. V. McIntosh, Michelle P. |
author_sort | Prankerd, Richard J. |
collection | PubMed |
description | Oxytocin is recommended by the World Health Organisation as the most effective uterotonic for the prevention and treatment of postpartum haemorrhage. The requirement for parenteral administration by trained healthcare providers and the need for the drug solution to be maintained under cold-chain storage limit the use of oxytocin in the developing world. In this study, a spray-dried ultrafine formulation of oxytocin was developed with an optimal particle size diameter (1-5 µm) to facilitate aerosolised delivery via the lungs. A powder formulation of oxytocin, using mannitol, glycine and leucine as carriers, was prepared with a volume-based median particle diameter of 1.9 µm. Oxytocin content in the formulation was assayed using high-performance liquid chromatography-mass spectroscopy and was found to be unchanged after spray-drying. Ex vivo contractility studies utilising human and ovine uterine tissue indicated no difference in the bioactivity of oxytocin before and after spray-drying. Uterine electromyographic (EMG) activity in postpartum ewes following pulmonary (in vivo) administration of oxytocin closely mimicked that observed immediately postpartum (0-12 h following normal vaginal delivery of the lamb). In comparison to the intramuscular injection, pulmonary administration of an oxytocin dry powder formulation to postpartum ewes resulted in generally similar EMG responses, however a more rapid onset of uterine EMG activity was observed following pulmonary administration (129 ± 18 s) than intramuscular injection (275 ± 22 s). This is the first study to demonstrate the potential for oxytocin to elicit uterine activity after systemic absorption as an aerosolised powder from the lungs. Aerosolised oxytocin has the potential to provide a stable and easy to administer delivery system for effective prevention and treatment of postpartum haemorrhage in resource-poor settings in the developing world. |
format | Online Article Text |
id | pubmed-3871608 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38716082013-12-27 Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries Prankerd, Richard J. Nguyen, Tri-Hung Ibrahim, Jibriil P. Bischof, Robert J. Nassta, Gemma C. Olerile, Livesey D. Russell, Adrian S. Meiser, Felix Parkington, Helena C. Coleman, Harold A. Morton, David A. V. McIntosh, Michelle P. PLoS One Research Article Oxytocin is recommended by the World Health Organisation as the most effective uterotonic for the prevention and treatment of postpartum haemorrhage. The requirement for parenteral administration by trained healthcare providers and the need for the drug solution to be maintained under cold-chain storage limit the use of oxytocin in the developing world. In this study, a spray-dried ultrafine formulation of oxytocin was developed with an optimal particle size diameter (1-5 µm) to facilitate aerosolised delivery via the lungs. A powder formulation of oxytocin, using mannitol, glycine and leucine as carriers, was prepared with a volume-based median particle diameter of 1.9 µm. Oxytocin content in the formulation was assayed using high-performance liquid chromatography-mass spectroscopy and was found to be unchanged after spray-drying. Ex vivo contractility studies utilising human and ovine uterine tissue indicated no difference in the bioactivity of oxytocin before and after spray-drying. Uterine electromyographic (EMG) activity in postpartum ewes following pulmonary (in vivo) administration of oxytocin closely mimicked that observed immediately postpartum (0-12 h following normal vaginal delivery of the lamb). In comparison to the intramuscular injection, pulmonary administration of an oxytocin dry powder formulation to postpartum ewes resulted in generally similar EMG responses, however a more rapid onset of uterine EMG activity was observed following pulmonary administration (129 ± 18 s) than intramuscular injection (275 ± 22 s). This is the first study to demonstrate the potential for oxytocin to elicit uterine activity after systemic absorption as an aerosolised powder from the lungs. Aerosolised oxytocin has the potential to provide a stable and easy to administer delivery system for effective prevention and treatment of postpartum haemorrhage in resource-poor settings in the developing world. Public Library of Science 2013-12-23 /pmc/articles/PMC3871608/ /pubmed/24376618 http://dx.doi.org/10.1371/journal.pone.0082965 Text en © 2013 Prankerd et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Prankerd, Richard J. Nguyen, Tri-Hung Ibrahim, Jibriil P. Bischof, Robert J. Nassta, Gemma C. Olerile, Livesey D. Russell, Adrian S. Meiser, Felix Parkington, Helena C. Coleman, Harold A. Morton, David A. V. McIntosh, Michelle P. Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries |
title | Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries |
title_full | Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries |
title_fullStr | Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries |
title_full_unstemmed | Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries |
title_short | Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries |
title_sort | pulmonary delivery of an ultra-fine oxytocin dry powder formulation: potential for treatment of postpartum haemorrhage in developing countries |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871608/ https://www.ncbi.nlm.nih.gov/pubmed/24376618 http://dx.doi.org/10.1371/journal.pone.0082965 |
work_keys_str_mv | AT prankerdrichardj pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries AT nguyentrihung pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries AT ibrahimjibriilp pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries AT bischofrobertj pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries AT nasstagemmac pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries AT olerileliveseyd pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries AT russelladrians pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries AT meiserfelix pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries AT parkingtonhelenac pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries AT colemanharolda pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries AT mortondavidav pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries AT mcintoshmichellep pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries |